Denali Therapeutics Inc.
TAK-594/DNL593
GRN-related frontotemporal dementia
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for TAK-594/DNL593 in GRN-related frontotemporal dementia are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Initial FTD-GRN patient data are expected in 2026”